Cagrilintide: Benefits, Dosage & Weight-Loss Potential Explained (2026)

Cagrilintide is rapidly emerging as one of the most exciting compounds in metabolic research. As a long-acting amylin analogue developed by Novo Nordisk, it targets satiety pathways that semaglutide and other GLP-1 receptor agonists largely bypass — making the combination of both compounds a potential breakthrough in obesity treatment.

In clinical trials, cagrilintide alone produced meaningful weight loss. But when researchers co-administered it with semaglutide in the REDEFINE program, the results were striking: participants lost up to 22.7% of body weight over 68 weeks — outcomes that rival bariatric surgery in some cohorts.

This guide covers what cagrilintide is, how it works mechanistically, what the clinical data shows, how it compares to other metabolic peptides, and what researchers need to know about its dosing profile.

What Is Cagrilintide?

Cagrilintide (INN; developmental code AM833) is a fatty acid-conjugated, long-acting analogue of amylin — a pancreatic peptide hormone co-secreted with insulin by beta cells in response to food intake. Native amylin has a very short half-life and causes aggregation issues, making it unsuitable for therapeutic use. Cagrilintide solves both problems through structural modifications that extend its half-life to approximately seven days, enabling once-weekly dosing.

Unlike semaglutide and other GLP-1 receptor agonists, cagrilintide does not primarily act through the GLP-1 receptor. Instead, it activates amylin receptors (AMY1–3) located in the area postrema, nucleus of the solitary tract, and the arcuate nucleus of the hypothalamus. This mechanistically distinct pathway is why combining the two compounds produces additive — and in some analyses, synergistic — effects on body weight and metabolic markers.

Pramlintide, the only FDA-approved amylin analogue currently on the market, requires multiple daily injections and produces modest weight loss. Cagrilintide's long-acting formulation is designed to overcome these limitations, making it a far more practical research and potential clinical tool.

How Cagrilintide Works: Mechanism of Action

Cagrilintide engages several complementary pathways that collectively reduce energy intake and support metabolic regulation:

1. Central Satiety Signaling
Amylin receptor activation in the area postrema — a circumventricular organ with direct access to systemic circulation — sends satiety signals to the hypothalamus. Cagrilintide mimics and extends this signalling, reducing meal size and caloric intake by increasing the perception of fullness.

2. Gastric Emptying Rate Reduction
Cagrilintide slows gastric motility, which prolongs the postprandial nutrient absorption window. This blunts post-meal glucose spikes and reduces the speed at which hunger returns after eating — an effect also shared (but through a different mechanism) by GLP-1 agonists.

3. Glucagon Suppression
Elevated postprandial glucagon contributes to hyperglycemia in type 2 diabetes and obesity. Cagrilintide, like native amylin, suppresses inappropriate glucagon secretion, helping to normalize post-meal glucose levels without causing hypoglycemia.

4. Hypothalamic Energy Homeostasis
Activation of amylin receptors in the arcuate nucleus modulates neuropeptide Y (NPY) and pro-opiomelanocortin (POMC) neurons — the two master regulators of energy balance. This central action may contribute to longer-term reductions in appetite that go beyond immediate meal-time satiety.

Clinical Trial Data: What the Research Shows

Cagrilintide's clinical development has moved quickly, with multiple Phase 2 and Phase 3 studies now reporting results.

Monotherapy Data (Phase 2)

In a Phase 2 dose-escalation trial (NCT03856047), adults with overweight or obesity who received cagrilintide 2.4 mg once weekly for 26 weeks lost a placebo-adjusted mean of 10.8% of body weight. This put it among the most effective single-agent weight-loss compounds studied at the time — ahead of liraglutide and comparable to early semaglutide data at equivalent durations.

CagriSema Combination (REDEFINE Phase 3)

The most consequential data comes from the REDEFINE trial series examining CagriSema — a fixed-dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg given as a single once-weekly subcutaneous injection.

Published findings from REDEFINE 1 (n=3,417 adults with obesity, no diabetes) showed:

• Mean body weight reduction of 22.7% at 68 weeks vs. 7.2% with placebo
• 68% of CagriSema-treated participants achieved ≥20% weight loss
• Significant improvements in waist circumference, blood pressure, and lipid profiles
• Side effect profile consistent with GLP-1/amylin drug classes (nausea, vomiting, injection site reactions)

REDEFINE 2 is evaluating CagriSema in adults with type 2 diabetes, where early data suggests both superior glycemic control and weight loss compared to semaglutide alone. REDEFINE 3 is examining cardiovascular outcomes.

Comparative Efficacy

To contextualise: semaglutide 2.4 mg (Wegovy) produces approximately 14.9% weight loss at 68 weeks. Retatrutide, the triple agonist (GIP/GLP-1/glucagon), produced ~24% weight loss in Phase 2. CagriSema at ~22.7% places it in elite company and represents the highest weight reduction for a dual-mechanism approach in a Phase 3 trial.

Cagrilintide Dosage: Research Protocol Overview

In clinical trials, cagrilintide has been studied using a gradual dose-escalation schedule to minimise gastrointestinal side effects. The following escalation schedule reflects the protocol used in Novo Nordisk's Phase 3 REDEFINE program:

When studied as monotherapy, cagrilintide followed a similar escalation: 0.25 mg → 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg, each dose maintained for four weeks before escalation. The purpose of slow titration is to allow gastrointestinal adaptation — nausea rates are substantially lower with gradual escalation compared to immediate high-dose administration.

Route of Administration: Subcutaneous injection (abdomen, thigh, or upper arm), once weekly. The long half-life of approximately 7 days supports the once-weekly schedule with stable steady-state plasma concentrations achieved by approximately week 5 of maintenance dosing.

Cagrilintide Side Effects: Safety Profile from Clinical Data

Cagrilintide's side effect profile is broadly consistent with the amylin and GLP-1 drug classes. In REDEFINE 1, the most commonly reported adverse events were gastrointestinal in nature:

• Nausea: ~41% of CagriSema participants (vs. ~14% placebo) — predominantly mild-to-moderate, dose-related
• Vomiting: ~20% of participants
• Diarrhea: ~23% of participants
• Constipation: ~18% of participants
• Injection site reactions: Mild, transient; more common with cagrilintide than semaglutide alone

Serious adverse events were uncommon. Hypoglycemia was not significantly elevated compared to placebo in the non-diabetic cohort. Gallbladder events (cholelithiasis) occurred at a rate consistent with other significant weight-loss interventions. No unique safety signals attributable specifically to cagrilintide's amylin mechanism were identified in Phase 3 data published through early 2026.

Notably, the slow dose-escalation protocol substantially attenuated GI side effects compared to earlier rapid-titration experiments, and discontinuation rates due to adverse events (~7%) were comparable to semaglutide monotherapy trials.

Cagrilintide vs. Other Metabolic Peptides

Cagrilintide vs. Semaglutide: Semaglutide acts on GLP-1 receptors; cagrilintide acts on amylin receptors. Semaglutide monotherapy produces ~14.9% weight loss at 68 weeks; cagrilintide monotherapy produces ~10.8% at 26 weeks. Their combination dramatically outperforms either alone, suggesting genuine mechanistic complementarity rather than simple additivity.

Cagrilintide vs. Retatrutide: Retatrutide (GIP/GLP-1/glucagon triple agonist) achieved ~24% weight loss in Phase 2 — slightly higher than CagriSema in Phase 3. However, direct comparisons are premature given different trial designs, durations, and populations. Both represent the leading edge of next-generation weight management research.

Cagrilintide vs. Tirzepatide: Tirzepatide (GIP/GLP-1 dual agonist, approved as Mounjaro/Zepbound) produces ~20–22% weight loss. CagriSema's ~22.7% is comparable, though the mechanisms are entirely different. Researchers note CagriSema may offer advantages in populations with differential GIP receptor responsiveness.

Cagrilintide vs. Pramlintide: Pramlintide is the only other approved amylin analogue. It requires 2–3 daily injections and produces only modest weight loss (~2–3 kg). Cagrilintide's structural modifications represent a generational leap in duration of action and weight-reduction efficacy.

Cagrilintide FAQ

Where to Buy Cagrilintide for Research

Cagrilintide is available through select research peptide suppliers for legitimate research purposes. When evaluating vendors, researchers should prioritise the following quality indicators:

• Third-party purity testing: Look for ≥98% purity confirmed by HPLC analysis from an independent laboratory
• Certificate of Analysis (COA): Every batch should have a publicly accessible or on-request COA with mass spectrometry confirmation
• US-based operations: Domestic suppliers offer faster shipping, easier quality verification, and greater regulatory accountability
• Transparent manufacturing: GMP-aligned synthesis processes and clear sourcing documentation
• Responsive support: Legitimate research suppliers provide documentation on request and have clear customer communication channels

Ascension Peptides is one supplier that meets these research-grade quality standards for cagrilintide and related metabolic peptides, offering third-party tested products with COA documentation available for each batch.